source
- Sanofi pauses phase 2 bronchiectasis trial of SAR445399 for strategic reasonsSanofi has halted a phase 2 study of its monoclonal antibody SAR445399 in adults with non‑cystic fibrosis bronchiectasis. The trial, which began in April, was a randomized, double‑blind, placebo‑co…
- Expedition Therapeutics raises $115M Series B to fund phase 2 COPD trial of DPP1 inhibitorExpedition Therapeutics, backed by Sanofi, announced a $115 million Series B financing round. The round was led by General Atlantic with participation from RA Capital, Vivo Capital, and existing i…